1. Anticoagulant use in patients with intracranial bleeding can increase bleeding risk. Mitigation includes careful monitoring and dose adjustments based on regular clotting tests.

2. Using anticoagulants in those with intracranial bleeding disorders heightens the risk of exacerbating bleeds. Risk reduction involves using the minimal effective dose and frequent neuroimaging.

3. The main risk of anticoagulants in intracranial bleeding disorders is increased hemorrhage. To minimize risks, clinicians should prioritize reversible agents and close monitoring of neurologic status.